Smith & Nephew plc (SNN) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Is Smith & Nephew plc stock overvalued or undervalued in 2026?
Smith & Nephew plc (SNN) trades at 19.8× earnings (P/E), below the median of the 246 healthcare companies over $2bn in Kaplio's universe. At the decade median (13.7×) $21 (-31 %); at its sector median (30.4×) $47 (+54 %).
Kaplio overview: Smith & Nephew plc
Market cap $13B · 52 weeks $26 – $37 (17 % below the high) · P/E 19.8× · 2027 expected P/E 12.7× · Dividend 2.6 % · Next earnings February 23, 2027 · expected EPS $1.21 · Closing price, Oct 29 · accounts published Aug 4.
- Valuation: P/E 19.8× (expensive).
- Business: ROIC 9 % (fair).
- Balance sheet: Net debt/EBITDA 2.1× (solid).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
At the decade median (13.7×) $21 (-31 %); at its sector median (30.4×) $47 (+54 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 3 of 7 pass
- R&D / Revenue 5.6 %, fails.
- 5y EPS growth 7.1 %, fails.
- ROIC 8.8 %, fails.
- Gross margin 68.3 %, borderline.
- FCF / Net Income 136.3 %, passes.
- Net debt / EBITDA 2.1×, passes.
- P/E vs own 10y history 19.8×, passes.
Against its peers (reference peers) — Smith & Nephew plc: P/E 19.8×; EV/EBITDA 9.4×; ROIC 8.8 %; $12.7B. Globus Medical, Inc. (P/E 21.3×; EV/EBITDA 11.3×; ROIC 10.5 %; $11.1B), Zimmer Biomet Holdings, Inc. (P/E 23.7×; EV/EBITDA 10.9×; ROIC 5.5 %; $18.6B), Stryker Corporation (P/E 32.3×; EV/EBITDA 20.5×; ROIC 7.2 %; $119B).
Expensive or cheap against its last ten years?
P/E at each close: today 19.8× · median 13.7× · minimum 6.7× · maximum 62.6× · cheap below 9.7× · expensive above 40.7×. It has been cheaper than today 57% of the time over its last ten years.
Dividend
tight (only raised recently) · Yield 2.6 % ($0.76 per share in 2025) · Years raising it 1 · 5-year growth +0 % a year · Free cash flow coverage 1.4× · With $1,000 invested today you'd collect $26.00 a year ($2.17 a month).
Profitability
| Return on Equity | 12.25% |
| Return on Invested Capital | 8.85% |
| Return on Assets | 5.81% |
| Gross Margin | 68.18% |
| Operating Margin | 16.69% |
| Net Margin | 10.08% |
Financial Health
| Debt / Equity | 0.73 |
| Current Ratio | 2.14 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 3.49 |
Price Performance
| 1 month | +12.80% |
| 3 months | -3.64% |
| Year-to-date | -7.31% |
| 1 year | -14.98% |
| 3 years | +36.74% |
| 5 years | -12.49% |
| 10 years | +6.07% |
Dividend History
Paid in the last 12 months: $0.7940 per share in 2 payments.
| Date | Amount |
|---|---|
| 2026-10-02 | $0.3120 |
| 2026-03-27 | $0.4820 |
| 2025-10-03 | $0.3000 |
| 2025-03-28 | $0.4620 |
| 2024-10-04 | $0.2880 |
| 2024-04-01 | $0.4620 |
| 2023-10-05 | $0.2880 |
| 2023-03-30 | $0.4620 |
| 2022-09-29 | $0.2880 |
| 2022-03-31 | $0.4620 |
Amounts adjusted for stock splits.
Related companies: SYK · ZBH · GMED · ABT · 0Y6X.L · MDT · 0R2S.L · 0HOY.L
Explore sector: Healthcare · Medical - Devices
More sections of SNN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks